TJ101

DRUG2 trials

Sponsors

TJ Biopharma Co., Ltd., Phrontline Biopharma

Conditions

Esophageal CancerLung Cancer (NSCLC)Pediatric Growth Hormone DeficiencyProstate CancerSolid Tumor Malignancies

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

RecruitingNCT07181473

Phrontline BiopharmaEsophageal Cancer, Lung Cancer (NSCLC), Prostate Cancer +1

Start: 2025-08-25End: 2027-09-15Target: 200Updated: 2026-01-12

Phase 3

A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

CompletedNCT04633057

TJ Biopharma Co., Ltd.Pediatric Growth Hormone Deficiency

Start: 2021-01-25End: 2023-07-31Updated: 2024-04-15